Ludwig Institute for Cancer Research
The Ludwig Institute for Cancer Research is a global non profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for human benefit.
Program Highlights
Cancer Epidemiology
Dr Luisa Villa (Director, LICR São Paulo Branch) and her colleagues are studying the links between human papilloma virus and cervical cancer to improve detection, prevention and treatment. Dr. Villa was elected to the Brazilian Academy of Sciences in 2007. More »
News
November 17, 2008
LICR Research Leads to US Pharmaceutical Licensing Deal
The international Ludwig Institute for Cancer Research (LICR) announced today that one of its spin-off companies, Life Science Pharmaceuticals, has licensed its lead cancer therapy candidate to pharmaceutical company Abbott.
October 22, 2008
Master Switch of Lymphatic Vessel Growth Identified
In a study published this week in Nature, investigators from the Melbourne Branch of the Ludwig Institute for Cancer Research (LICR), the Institute for Molecular Bioscience (Australia) and the FIRC Institute of Molecular Oncology (Italy) report that a “genetic switch†directs the formation of new lymphatic vessels.